CLEC19A

Across TCGA pan-cancer cohorts, CLEC19A RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of CLEC19A’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where CLEC19A RNA is repressed in tumor relative to normal tissue. In most cancer types CLEC19A is over-expressed in tumor, although a few such as LUSC and COAD show the opposite, repressed pattern.

LUSC, COAD, and STAD are the cancer types where CLEC19A tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CLEC19A RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUSC	Male	II,III,IV	−0.438	<.001	7	view →
COAD	All	II,III,IV	−0.137	<.001	6	view →
STAD	Male	All	+0.184	.023	4	view →
BRCA	Female	All	+0.083	.007	4	view →
KICH	All	All	+0.066	.001	4	view →
LUAD	All	All	−0.269	.015	3	view →
PAAD	Female	All	+0.165	<.001	2	view →
READ	All	III,IV	−0.160	.033	2	view →
PRAD	All	All	+0.144	.003	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

CLEC19A–LUSC

Open the LUSC breakdown →